Koichi Azuma

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Idiopathic Pulmonary Fibrosis

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Cancer research communications

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Daiki Murata, Koichi Azuma, Kenta Murotani, Akihiko Kawahara, Yuuya Nishii, Takaaki Tokito, Tetsuro Sasada, Tomoaki Hoshino
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy. Cancer immunology, immunotherapy : CII 73 (11) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications (2024)
Feifei Wei, Koichi Azuma, Yoshiro Nakahara, Haruhiro Saito, Norikazu Matsuo, Tomoyuki Tagami, Taku Kouro, Yuka Igarashi, Takaaki Tokito, Terufumi Kato, Tetsuro Kondo, Shuji Murakami, Ryo Usui, Hidetomo Himuro, Shun Horaguchi, Kayoko Tsuji, Kenta Murotani, Tatsuma Ban, Tomohiko Tamura, Yohei Miyagi, Tetsuro Sasada
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. Journal for immunotherapy of cancer 11 (7) (2023)
Daiki Murata, Koichi Azuma, Norikazu Matsuo, Kenta Murotani, Goushi Matama, Akihiko Kawahara, Tetsuro Sasada, Takaaki Tokito, Tomoaki Hoshino
Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer medicine (2023)
Norikazu Matsuo, Koichi Azuma, Kenta Murotani, Daiki Murata, Goushi Matama, Akihiko Kawahara, Takashi Kojima, Takaaki Tokito, Tomoaki Hoshino
Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Thoracic cancer (2023)
Daiki Murata, Koichi Azuma, Goushi Matama, Yoshiaki Zaizen, Norikazu Matsuo, Kenta Murotani, Takaaki Tokito, Tomoaki Hoshino
Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer. Thoracic cancer (2022)
Koichi Azuma, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Norikazu Matsuo, Hidenobu Ishii, Takaaki Tokito, Akihiko Kawahara, Kenta Murotani, Tetsuro Sasada, Yohei Miyagi, Tomoaki Hoshino
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model. Journal for immunotherapy of cancer 10 (5) (2022)
Hidenobu Ishii, Koichi Azuma, Takayuki Shimose, Hiroshige Yoshioka, Takayasu Kurata, Naoki Shingu, Masaki Okamoto, Yosuke Kawashima, Isamu Okamoto
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003). Thoracic cancer (2022)
Daiki Murata, Koichi Azuma, Saeko Tokisawa, Takaaki Tokito, Tomoaki Hoshino
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer. Thoracic cancer 13 (20) (2022)
Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Takashi Kinoshita, Norikazu Matsuo, Yoshiko Naito, Takaaki Tokito, Kazuhiko Yamada, Jun Akiba, Tomoaki Hoshino
Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC. Thoracic cancer 11 (4) (2020)
Norikazu Matsuo, Koichi Azuma, Satoshi Hattori, Junya Ohtake, Akihiko Kawahara, Hidenobu Ishii, Takaaki Tokito, Kazuhiko Yamada, Yuji Shibata, Tadasuke Shimokawaji, Tetsuro Kondo, Terufumi Kato, Haruhiro Saito, Kouzo Yamada, Tetsuro Sasada, Tomoaki Hoshino
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. International journal of cancer 144 (5) (2018)
Eiji Iwama, Kazuko Sakai, Koichi Azuma, Daijiro Harada, Kaname Nosaki, Katsuyuki Hotta, Makoto Nishio, Takayasu Kurata, Tatsuro Fukuhara, Hiroaki Akamatsu, Koichi Goto, Takayuki Shimose, Junji Kishimoto, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer science 109 (12) (2018)
Haruyasu Murakami, Hiroshi Nokihara, Hidetoshi Hayashi, Takashi Seto, Keunchil Park, Koichi Azuma, Chun-Ming Tsai, James Chih-Hsin Yang, Makoto Nishio, Sang-We Kim, Katsuyuki Kiura, Akira Inoue, Koji Takeda, Jin-Hyoung Kang, Tomoki Nakagawa, Kentaro Takeda, Rio Akazawa, Yuichiro Kaneko, Masashi Shimazaki, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer science 109 (9) (2018)
Koichi Azuma, Makoto Nishio, Hidetoshi Hayashi, Katsuyuki Kiura, Miyako Satouchi, Shunichi Sugawara, Toyoaki Hida, Yasuo Iwamoto, Akira Inoue, Koji Takeda, Satoshi Ikeda, Tomoki Nakagawa, Kentaro Takeda, Seitaro Asahina, Kanji Komatsu, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Cancer science 109 (8) (2018)